Congress mandates anthrax defense plan, locks in long-term pharma contracts
H.R. 2707 — Protecting American Families and Servicemembers from Anthrax Act · Filed by Donald Davis (D-NC) · 19 cosponsors · Introduced Apr 8, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Departments of Health and Human Services and Defense to jointly develop a 10-year strategy within 180 days for maintaining and replenishing anthrax countermeasures (drugs, vaccines, and treatments) in the Strategic National Stockpile and military supplies. The bill mandates annual reporting to Congress on anthrax threats, federal programs addressing them, and efforts to ensure adequate countermeasures for military dependents, with a focus on manufacturer sustainability and innovation.
Why we flagged it
The bill's core mechanism is a directive to federal agencies to develop and maintain a strategic defense plan against anthrax threats, with mandatory reporting. This is a straightforward public health and national security measure, not a regulatory carve-out or appropriation.
What the text implies
- The bill's focus on 'manufacturer sustainability and innovation' may create implicit pressure to award contracts or favorable procurement terms to anthrax countermeasure manufacturers, potentially inflating costs or limiting competitive bidding.
- Annual classified reporting to Congress may obscure budget allocations and procurement decisions from public scrutiny, reducing transparency despite the bill's stated accountability purpose.
The full analysis lists 4 implications of this text.
Who stands to gain
anthrax countermeasure manufacturers; pharmaceutical and biological product companies with FDA-approved anthrax treatments; defense contractors involved in military medical countermeasure supply chains